The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 22: 2964 - 2968

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.22.018

Clinical Research

Value of microbiology rapid on⁃site evaluation in severe pneumonia

  • Xingle YANG ,
  • Tingting XIA ,
  • Chunlei ZUO ,
  • Jiaxin. SHI
Expand
  • *.Jinzhou Medical University，Jinzhou 121000，China

Received date: 2023-07-15

  Online published: 2023-12-11

Fold

Abstract

Objective To investigate the potential application value of microbiology rapid on-site evaluation （M-ROSE） in patients with severe pneumonia. Methods Sixty patients with severe pneumonia admitted to our hospital from February 2021 to February 2023 were randomly divided into two groups， with 30 cases in each group. The control group was given empirical antibacterial therapy， while the M-ROSE group received antibacterial therapy according to the rapid detection results. The level of interleukin 6 （IL-6） and IL-10 was detected on day 1 and 7， respectively； the level of inflammatory indicators （C-reactive protein （CRP） and white blood cell （WBC）） on day 1 and day 7 after enrollment were recorded， and the difference of fever duration， length of mechanical ventilation， length of stay in ICU， 28-day mortality between the two groups was compared. Results The expression level of IL-6， IL-10 and IL-6/IL-10 in M-ROSE group on day 7 was lower than that in experience group （P < 0.05）. The duration of fever disappearance， length of mechanical ventilation and length of stay in ICU in M-ROSE group were shorter than those in the control group （P < 0.05）. There was no significant difference in 28-day mortality between the two groups （P > 0.05）. Conclusion M-ROSE is a valuable tool for the initial assessment of etiology in patients with severe pneumonia. Its potential value is to improve symptoms and inflammation， and shorten length of mechanical ventilation and length of stay in ICU.

Key words： microbiology rapid on-site evaluation （M-ROSE）; severe pneumonia; cytokines; treatment; application value

Cite this article

Xingle YANG , Tingting XIA , Chunlei ZUO , Jiaxin. SHI . Value of microbiology rapid on⁃site evaluation in severe pneumonia[J]. The Journal of Practical Medicine, 2023 , 39(22) : 2964 -2968 . DOI: 10.3969/j.issn.1006-5725.2023.22.018

References

1 NAIR G B， NIEDEMAN M S. Updates on community acquired pneumonia management in the ICU ［J］. Pharmacol Ther， 2021， 217：107663.
2 DE PASCALE G， BELLO G， ANTONELLI M. Steroids in severe pneumonia： a literature review ［J］. Minerva Anestesiol， 2011， 77（9）：902-910.
3 CHALMERS J D， TAYLOR J K， MANDAL P， et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care ［J］. Clin Infect Dis， 2011， 53（6）：503-511.
4 冯靖. 介入呼吸病学的快速现场评价［J］. 现代实用医学，2016，28（1）：5-7.
5 金旭如，陈成水. 浅谈快速现场评价在呼吸系统疾病诊断中的应用［J］. 中华结核和呼吸杂志， 2018， 41（6）：507-508.
6 房宇坤，李玉，王剑，等. 微生物学快速现场评估在支气管镜下诊断肺部感染的价值［J］. 中国当代医药，2020，27（14）：4-7，29.
7 TAO Y， SONG L， FU H， et al. Application of microbiological rapid on-site evaluation in respiratory intensive care units： a retrospective study ［J］. Ann Transl Med， 2022， 10（1）：7.
8 MANDELL L A， WUNNDERINK R G， ANZUETO A， et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults ［J］. Clin Infect Dis， 2007， 44（）：S27-S72.
9 于翠香， 王西艳. 《中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南（2018年版）》解读［J］. 中国医刊，2021，56（09）：951-953.
10 曹季平. 基于《社区获得性肺炎诊断和治疗指南（2016版）》对医院成人CAP患者抗菌药物使用的相关因素分析［J］. 抗感染药学，2020，17（3）：323-327.
11 LV M， ZHU C， ZHU C， et al. Clinical values of metagenomic next-generation sequencing in patients with severe pneumonia： a systematic review and meta-analysis ［J］. Front Cell Infect Microbiol， 2023， 13：1106859.
12 张瑾，邓扬嘉，何苗，等. 免疫缺陷患者重症肺炎诊断进展［J］.中华肺部疾病杂志（电子版），2021，14（3）：383-386.
13 JASSIM T K， FERREIRA J E， MURPHY M B， et al. The use of diagnostic patterns for interventional cytopathology during rapid on-site evaluation and final classification ［J］. Semin Diagn Pathol， 2022， 39（6）：394-404.
14 徐春华，钟健，王伟，等. 径向超声联合快速现场评估在肺外周病变的诊断价值［J］. 中国呼吸与危重监护杂志，2022，21（7）：493-497.
15 XU Y， WANG M， CHEN D， et al. Inflammatory biomarkers in older adults with frailty： a systematic review and meta-analysis of cross-sectional studies ［J］. Aging Clin Exp Res， 2022， 34（5）：971-987.
16 刘武胜，李如梅，宋志峰，等. 重症肺炎患者肺泡灌洗液的炎症因子动态变化特点及临床意义［J］. 临床肺科杂志，2016，21（5）：831-834.
17 唐劲松，宣春，林景涛，等. C-反应蛋白、白介素-6及降钙素原检测在新冠肺炎中的临床意义［J］. 实用医学杂志，2020，36（7）：839-841.
18 杨小纯，金玥，蔡悦. 羌活胜湿汤加减方对强直性脊柱炎患者脊柱功能及急性时相反应物指标的影响［J］. 实用医学杂志，2021，37（18）：2423-2427.
19 YOSHIMURA J， YAMAKAWA K， OHTA Y， et al. Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia： The GRACE-VAP Randomized Clinical Trial ［J］. JAMA Netw Open， 2022， 5（4）：e226136.
20 JARA M C， FREDIANI A V， ZEHETMEYER F K， et al. Multidrug-Resistant Hospital Bacteria： Epidemiological Factors and Susceptibility Profile ［J］. Microb Drug Resist， 2021， 27（3）：433-440.
Options
Outlines

/

〈 〉